| **Variable** | **Standard**, N = 4,1301 | **ACE-inhibitor therapy**, N = 4,1531 | **p-value**2 |
| --- | --- | --- | --- |
| **Age Group** |  |  | 0.2 |
| ≤ 65 | 2,297 (56%) | 2,256 (54%) |  |
| > 65 | 1,833 (44%) | 1,897 (46%) |  |
| **Systolic Blood Pressure** | 133 (17) | 134 (17) | 0.2 |
| **Gender** |  |  | 0.022 |
| Male | 3,427 (83%) | 3,365 (81%) |  |
| Female | 703 (17%) | 788 (19%) |  |
| **History of Diabetes** |  |  | 0.081 |
| No Diabetes | 3,472 (84%) | 3,431 (83%) |  |
| Diabetes | 658 (16%) | 722 (17%) |  |
| **History of Hypertension** |  |  | 0.7 |
| No Hypertension | 2,262 (55%) | 2,257 (54%) |  |
| Hypertension | 1,868 (45%) | 1,896 (46%) |  |
| 1n (%); Mean (SD) | | | |
| 2Pearson's Chi-squared test; Welch Two Sample t-test | | | |